Trial Profile
An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject With Fragile X Syndrome
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Arbaclofen (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions; Registrational
- Sponsors Seaside Therapeutics
- 23 May 2023 According to Allos Pharma Media release, the company receives FDA Guidance for the Design of a Phase 3 Trial to Support a New Drug Application for Treatment of Fragile X Syndrome.
- 10 Apr 2015 New trial record